Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

Also called NCT07211035

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Amplifi Vascular, Inc. (from the registry)
Registry
  • NCT NCT07211035
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07211035. Randomized; single masking; primary purpose treatment. Start 2026-05-12 (actual); primary completion 2027-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)
Acronym
AMPLIFI-1
Condition
End Stage Kidney Disease (ESRD)
Intervention (Device)
The Amplifi System is a temporary extracorporeal blood pump designed to deliver controlled flow through a peripheral vein for 24-72 hours prior to AVF creation.
Intervention (Procedure)
Standard of Care (AVF creation)
Lead sponsor
Amplifi Vascular, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07211035
Content hash
a35820fcecca3602eaf09bfb8a897371b148089efcb9f55a64743ddedfa507e9